Business Context and Reporting Period
This Form 6-K filing is submitted by FSD Pharma Inc., a foreign private issuer, for the month of December 2023. The report was signed on December 14, 2023, by Nathan Coyle, Chief Financial Officer. The filing serves to disclose a material change previously reported on November 23, 2023, as indicated in Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural report referencing a prior material change rather than a financial statement.
Material Changes
- The registrant reports a material change that occurred on November 23, 2023.
- Details of the change are contained in the attached Material Change Report (Exhibit 99.1), the text of which is not included in the provided input.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly references the existence of a material change report.
Investor Verification Checklist
- Verify the specific nature of the material change reported on November 23, 2023, by reviewing Exhibit 99.1.
- Confirm the current operational status of FSD Pharma Inc. following the reported change.
- Note that the company name in the metadata (Quantum Biopharma Ltd.) differs from the registrant name in the filing (FSD Pharma Inc.); verify if this indicates a name change or a data discrepancy.